Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

Farhad Ravandi, Ellen K. Ritchie, Hamid Sayar, Jeffrey E. Lancet, Michael Craig, Norbert Vey, Stephen A. Strickland, Gary J. Schiller, Elias Jabbour, Harry P. Erba,

The Lancet Oncology · 2015 · 157 citations · 27 references

DOIFull text

Open access

Concepts

References

27